Scholar Rock
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor sign...
Latest News
14 hours ago · seekingalpha.com
Scholar Rock Holding Corporation (SRRK) Presents at UBS Global Biopharma Conference 2026 TranscriptScholar Rock Holding Corporation ( SRRK ) UBS Global Biopharma Conference 2026 November 16, 2026 5:00 AM EST Company Participants David Hallal - CEO & Chairman of the Board Conference Call Participants Michael Yee - UBS Investment Bank, Research Division Presentation Michael Yee UBS Investment Bank, Research Division Good morning, everyone. Thank you for joining us on our next session here at the UBS Global Biopharma Conference.
6 days ago · marketbeat.com
What Scholar Rock (SRRK) Said on Its Q3 Earnings CallScholar Rock NASDAQ: SRRK reported $0.6 million in third-quarter revenue from initial shipments of its newly approved spinal muscular atrophy treatment ISEMBYLD, while executives said insurance and reimbursement hurdles are likely to push most enrolled patients' first infusions into 2027.
6 days ago · seekingalpha.com
Scholar Rock Holding Corporation (SRRK) Q3 2026 Earnings Call TranscriptScholar Rock Holding Corporation (SRRK) Q3 2026 Earnings Call Transcript
6 days ago · zacks.com
Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Beats Revenue EstimatesScholar Rock Holding Corporation (SRRK) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $0.9 per share a year ago.
2 months ago · seekingalpha.com
Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In PlayScholar Rock Holding Corporation maintains a "Strong Buy" rating following FDA approval of ISEMBYLD [apitegromab] for SMA in patients ≥2 years old. SRRK targets a $2B+ market opportunity in SMA, with expansion potential into younger populations, subcutaneous formulations, and new indications like FSHD. Regulatory catalysts include planned MAA resubmission in Europe and anticipated JNDA filing in Japan by year-end 2026, leveraging a validated manufacturing facility.
2 months ago · seekingalpha.com
Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment TranscriptScholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript
2 months ago · benzinga.com
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular AtrophyThe U.S. Food and Drug Administration on Friday approved ISEMBYLD (apitegromab-mstn) from Scholar Rock (NASDAQ:SRRK) for spinal muscular atrophy (SMA) in adults and pediatric patients aged 2 years and older.
2 months ago · reuters.com
Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vialScholar Rock on Monday set a list price of $11,659 per single-use vial for its newly approved spinal muscular atrophy drug, the first therapy that directly targets muscle loss in patients with the rare genetic disorder.
2 months ago · benzinga.com
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving PremarketShares of Scholar Rock Holding Corp (NASDAQ:SRRK) rose sharply in pre-market trading after the company announced the FDA approval of ISEMBYLD (apitegromab-mstn), the first and only muscle-targeted treatment for children and adults with Spinal Muscular Atrophy (SMA).
2 months ago · businesswire.com
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced that the FDA has approved ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children two years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove SRRK